Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2011-04-11 Board/Management Inform…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo AB announces that Robin Wright resigns as CFO
Board/Management Information Classification · 1% confidence The document is a press release dated April 11, 2011, announcing that Robin Wright has resigned from the position of Chief Financial Officer (CFO) of Orexo AB, effective April 30. This content directly relates to a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is a clear announcement of a CFO resignation, fitting the MANG category perfectly.
2011-04-11 English
Orexo AB meddelar att Robin Wright avgår som finanschef
Board/Management Information Classification · 1% confidence The document is a press release dated April 11, 2011, announcing that Robin Wright is resigning from his position as Chief Financial Officer (CFO) and leaving the company at the end of April. This content directly relates to a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and clearly serves as an announcement of a management change.
2011-04-11 Swedish
Report from Orexo AB’s Annual General Meeting, 7 April 2011
AGM Information Classification · 1% confidence The document is explicitly titled 'Report from Orexo AB's Annual General Meeting, 7 April 2011'. It details resolutions passed regarding the financial statements, re-election of the Board of Directors, director fees, and share plans, which are all standard items discussed and approved at an Annual General Meeting (AGM). This directly corresponds to the AGM Information category.
2011-04-07 English
Kommuniké från Orexo AB:s årsstämma den 7 april 2011
AGM Information Classification · 1% confidence The document is explicitly titled "Kommuniké från Orexo AB:s årsstämma den 7 april 2011" (Communiqué from Orexo AB's Annual General Meeting on April 7, 2011). It details the decisions made during the AGM, including the approval of financial statements, election of the board of directors, setting remuneration, and approving share-based incentive programs. These contents directly correspond to the scope of an Annual General Meeting (AGM) event. Therefore, the appropriate classification is AGM-R.
2011-04-07 Swedish
Abstral® är lanserad och nu tillgänglig i USA
Regulatory Filings Classification · 1% confidence The document is a press release dated April 4, 2011, announcing the launch of the drug Abstral in the USA by Orexo AB's partner. It contains key business updates, market information, executive commentary, and contact details. Crucially, the final note states: "Informationen är sådan som Orexo AB (publ) ska offentliggöra enligt lagen om handel med finansiella instrument och/eller lagen om värdepappersmarknaden. Informationen lämnades för offentliggörande den 4 april 2011 kl. 14:15." This structure strongly indicates a mandatory regulatory disclosure of material information. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a specific transaction report (like DIRS or POS), and it is a general announcement of material business news required by securities law, it best fits the general 'Regulatory Filings' category (RNS) or potentially an Earnings Release (ER) if it contained financial results, but it primarily focuses on a product launch and regulatory milestone (FDA approval/REMS). Given the nature of a press release announcing a significant business event required for public disclosure, RNS is the most appropriate general regulatory fallback. It is not a Call Transcript (CT), Investor Presentation (IP), or a specific financial statement.
2011-04-04 Swedish
Abstral® launched and now available in the United States
Earnings Release Classification · 1% confidence The document is explicitly labeled as a "Press release" dated April 4, 2011, announcing the launch of a product (Abstral) in the US market by a partner company. It contains key business updates, contact information, and concludes with a statement that the information is required to be disclosed pursuant to the Swedish Securities Markets Act. This format is characteristic of a general corporate announcement or news release, which typically falls under the 'Regulatory Filings' (RNS) category as a miscellaneous regulatory disclosure, as it does not fit the specific definitions for 10-K, ER, IR, DIV, etc. It is not a transcript (CT), a formal report (AR, IR), or a specific shareholder/insider filing (DVA, DIRS). FY 2011
2011-04-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.